BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
BioNTech SE (Nasdaq: BNTX, "BioNTech") and Kite, a Gilead Company (Nasdaq: GILD, "Kite") today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility's assets and leases in Gaithersburg, MD, from Kite. The transaction was announced on July 19, 2021.
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses are expected to be delivered from October 2021 through April 2022. This brings the total number of doses to be supplied by the companies to the U.S. government under its existing supply agreement to 500 million. In a separate announcement on June 10, 2021, Pfizer and BioNTech shared plans to provide the U.S. government with 500 million doses of the companies' COVID-19 vaccine for donation to the world's poorest nations.
Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases
PALM BEACH, Fla., /PRNewswire/ -- According to WebMD, this week the nation's top health officials Tuesday that the Delta variant of the coronavirus is racing through and other parts of the world and now is responsible for 83% of all U.S. cases alone. That's a massive increase from a week ago, when Delta was seen as responsible for just more than half of new cases, CDC Director , MD, told a Senate committee. "The best way to prevent the spread of COVID-19 variants is to prevent the spread of disease, and vaccination is the most powerful tool we have," she said. Meanwhile, several states in the South are reporting a large increase in COVID-19 cases, particularly in areas with low vaccination rates, according , , and are reporting full-fledged outbreaks, and neighboring states such as , , , , , and are following behind. to the National Institutes of Health (NIH): "When variants of SARS-CoV-2 (the virus that causes COVID-19) emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues analyzed blood cell samples from 30 people who had contracted and recovered from COVID-19 prior to the emergence of virus variants. They found that one key player in the immune response to SARS-CoV-2—the CD8+ T cell—remained active against the virus." Active biotech companies in the market this week include (OTCQB: BVAXF) (CSE: BIOV), . (NYSE: PFE), (NYSE: JNJ), (NASDAQ: MRNA), (NASDAQ: SRNE).
Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as "Biovac," a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union.
BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
-- Kite Remains Focused on Rapid Advancement of Current CAR T-Cell Therapies to Reach More Patients and Further Optimize Therapeutic Potential of Cell Therapy --
Thinking about trading options or stock in Moderna, AMC Entertainment, BioNTech, Intel Corp, or Apple?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, AMC, BNTX, INTC, and AAPL.